NCT06054217Phase 2Unknown

Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex

Study sponsor: Tarsus Pharmaceuticals, Inc. · TARS

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-06-15Estimated

Enrollment · participants36Estimated

Source updated2024-04-09Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Meibomian Gland Dysfunction; Demodex Infestation of Eyelid; Blepharitis; Demodectic Blepharitis

Treatments or interventions studied

Vehicle of TP-03DrugAlso known as Exploratory Vehicle

Primary outcomes · main study measures

measure: Treatment Emergent Adverse Events (TEAEs); description: TEAEs related (definitely or potentially) to treatment summarized by MedDRA preferred term. TEAEs related (definitely or potentially) to treatment summarized by MedDRA preferred term.; timeFrame: 85 days

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history